Regulatory & Legal

Establishment Labs has submitted its innovative Motiva implants for FDA approval in reconstruction, promising a new era for post-mastectomy care.

Anfield Energy appoints financial expert Lubica Niemann as CFO, signaling a strategic move to manage NASDAQ compliance and its ambitious US uranium production goals.

Frontera's new prepayment pact with Chevron shores up its finances and locks in crude sales, highlighting a strategic win in a volatile oil market.

Valens Semiconductor's 2024 ESG report details major drops in emissions and energy use, but how do these gains stack up in the high-stakes tech world?

As its partnership with Rio Tinto's Nuton ends, Arizona Sonoran will independently advance its massive copper project, betting on strong economics.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

Once a cannabis fund, WEDG has completed its rebrand to Nuclear Diamond Batteries, Inc., betting its future on a patented, decades-long power source.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

With a massive IDR 200 billion capital boost from LDA Capital, Indonesian tech firm NANO is set to execute nearly IDR 5 trillion in contracts.

A battery innovator just won a key DOE grant to tackle a decades-old nuclear problem. Their secret weapon? Tiny carbon spheres.

Saving for a home is faster than in 2022, but a new report reveals a stark divide, with some facing a 30-year wait while others can buy in under two.

In crisis-hit Burundi, a unique mentorship program is tackling poverty and deep-seated stigma to ensure that girls don't just stay in school—they thrive.

Biomaterials firm Bolt Projects posts huge revenue gains and raises 2026 guidance, but a looming Nasdaq delisting threat casts a shadow on its future.

Everybody Loves Languages' CEO and CFO are taking the company private, raising questions about minority shareholder value and the firm's future strategy.

An FDA setback for its new mastitis drug prompts ImmuCell to double down on its profitable calf health franchise, First Defense®, in a major strategic shift.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

Croatian firm Orqa is building a global network to produce one million drones annually, challenging market leaders and securing allied defense supply chains.

Tevogen's Dr. Ryan Saadi donates over $88,000 in company stock to a UN-recognized charity, bolstering educational programs for underserved children.

A new cell-free therapy for the fatal lung disease IPF is heading to clinical trials, thanks to a key manufacturing partnership. Here's what it means.

Chinese insurtech Huize is cutting back on financial reports to focus on strategy, but its latest data shows a complex picture of soaring premiums and slowing new user growth.